Identification
- Summary
Technetium Tc-99m sulfur colloid is a radiopharmaceutical diagnostic agent used for the localization of lymph nodes, evaluation of peritoneovenous (LeVeen) shunt patency, imaging areas of functioning reticuloendothelial cells, and gastrointestinal imaging.
- Generic Name
- Technetium Tc-99m sulfur colloid
- DrugBank Accession Number
- DB09397
- Background
Technetium 99m sulfur colloid is a radiopharmaceutical diagnostic agent used in the evaluation of various conditions including lymph node metastases in breast cancer, detection of shunt patency, imaging of reticuloendothelial cells for assessment of liver function, and studies of esophageal transit and gastroesophageal reflux. Following injection or oral administration, single photon emission computer tomography (SPECT) imaging is performed using a gamma camera to detect technetium-99m decay. This is possible as Technetium-99m decays by isomeric transition to technetium-99 through the release of a gamma ray. Depending on site of administration and intended usage, Technetium 99m sulfur colloid enters the capillaries and is transported to the lymph nodes (subcutaneous injection), mixes with peritoneal fluid (intraperitoneal injection), is taken up by reticulocytes (intravenous injection), or enters the gastroesphageal tract (oral administration).
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Technetium Tc-99m sulfur colloid (DB09397)
- Weight
- Average: 355.39
Monoisotopic: 354.682823946 - Chemical Formula
- S8Tc
- Synonyms
- Technetium (99mTc) sulfur colloid
- Technetium 99m sulfur colloid
- Technetium Tc 99m sulfur colloid
- Technetium Tc-99m Sulfur Colloid
Pharmacology
- Indication
Technetium 99m sulfur colloid is indicated as a diagnostic agent in adults for the following tests: localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma; and evaluation of peritoneo-venous (LeVeen) shunt patency. It is indicated in both adult and pediatric patients for: imaging areas of functioning reticuloendothelial cells in the liver, spleen and bone marrow; and studies of esophageal transit and gastroesophageal reflux, and detection of pulmonary aspiration of gastric contents.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Following injection or oral administration, single photon emission computer tomography (SPECT) imaging is performed using a gamma camera to detect technetium-99m decay. This is possible as Technetium-99m decays by isomeric transition to technetium-99 through the release of a gamma ray.
- Absorption
When administered subcutaneously, Technetium Tc 99m Sulfur Colloid enters the lymphatic capillaries and is transported with lymph to lymph nodes where it can be used to detect drainage of primary tumours. When administered by intraperitoneal injection, Technetium Tc 99m Sulfur Colloid mixes with the peritoneal fluid where the rate of clearance from the cavity allows assessment of shunt patency. When administered by intravenous injection, Technetium Tc 99m Sulfur Colloid is taken up by the reticuloendothelial system (RES), allowing RES rich structures to be imaged. Uptake of the radioactive colloid by organs of the RES is dependent upon both their relative blood flow rates and the functional capacity of the phagocytic cells. When administered orally, Technetium Tc 99m sulfur colloid can be used in esophageal transit studies, gastroesophageal reflux scintigraphy, and for the detection of pulmonary aspiration of gastric contents. This is possible as the active substance is not absorbed from the GI tract.
- Volume of distribution
Following oral ingestion, Technetium Tc 99m Sulfur Colloid is distributed primarily through the gastrointestinal tract.
- Protein binding
Not Available
- Metabolism
In the average patient 80 to 90% of the injected collodial particles are phagocytized by the Kupffer cells of the liver, 5 to 10% by the spleen and the balance by the bone marrow.
- Route of elimination
Following oral ingestion, elimination is primarily through the feces.
- Half-life
Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours. Following intravenous administration, Technetium Tc 99m Sulfur Colloid Injection is rapidly cleared from the blood by the reticuloendothelial system with a nominal half-life of approximately 2 1/2 minutes.
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The most frequently reported adverse reactions, across all categories of use and routes of administration, include rash, allergic reaction, urticaria, anaphylaxis/anaphylactic shock, and hypotension. Less frequently reported adverse reactions are fatal cardiopulmonary arrest, seizures, dyspnea, bronchospasm, abdominal pain, flushing, nausea, vomiting, itching, fever, chills, perspiration, numbness, and dizziness. Local injection site reactions, including burning, blanching, erythema, sclerosis, swelling, eschar, and scarring, have also been reported. Anaphylactic reactions including rare fatalities have occurred following intravenously administered Technetium Tc 99m Sulfur Colloid. Radiation-emitting products, including Technetium Tc 99m Sulfur Colloid Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Take with food. For pediatric patients, orally administered Technetium Tc-99m sulfur colloid should be given with milk, or if administered by nasogastric tube, it should be given with milk or dextrose.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Kit for the Prepartion of Technetium Tc99m Sulfur Colloid Kit 18.1 mg/10mL Intravenous; Oral; Subcutaneous Sun Pharmaceutical Industries, Inc. 1978-04-19 Not applicable US 
Categories
- ATC Codes
- V09DB05 — Technetium (99mtc) sulfur colloid
- Drug Categories
- Compounds used in a research, industrial, or household setting
- Diagnostic Radiopharmaceuticals
- Diagnostic Uses of Chemicals
- Hepatic and Reticulo Endothelial System
- Indicators and Reagents
- Laboratory Chemicals
- Radioactive Diagnostic Agent
- Radiopharmaceutical Activity
- Radiopharmaceuticals
- Sulfur Compounds
- Technetium (99Mtc), Particles and Colloids
- Technetium Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as organic transition metal salts. These are organic salt compounds containing a transition metal atom in its ionic form.
- Kingdom
- Organic compounds
- Super Class
- Organic salts
- Class
- Organic metal salts
- Sub Class
- Organic transition metal salts
- Direct Parent
- Organic transition metal salts
- Alternative Parents
- Not Available
- Substituents
- Organic transition metal salt
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 556Q0P6PB1
- CAS number
- Not Available
- InChI Key
- FJTPHHNWVXNMEK-NLQOEHMXSA-N
- InChI
- InChI=1S/S8.Tc/c1-2-4-6-8-7-5-3-1;/i;1+2
- IUPAC Name
- octathiocane (99Tc)technetium
- SMILES
- [99Tc].S1SSSSSSS1
References
- General References
- Giovinazzo H, Kumar P, Sheikh A, Brooks KM, Ivanovic M, Walsh M, Caron WP, Kowalsky RJ, Song G, Whitlow A, Clarke-Pearson DL, Brewster WR, Van Le L, Zamboni BA, Bae-Jump V, Gehrig PA, Zamboni WC: Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer. Cancer Chemother Pharmacol. 2016 Mar;77(3):565-73. doi: 10.1007/s00280-015-2945-y. Epub 2016 Jan 28. [Article]
- Shih WJ, Domstad PA, Friedman B, DeLand FH: Intrathoracic abnormalities demonstrated by technetium-99m sulfur colloid imaging. Clin Nucl Med. 1986 Nov;11(11):792-6. [Article]
- Bowen SR, Chapman TR, Borgman J, Miyaoka RS, Kinahan PE, Liou IW, Sandison GA, Vesselle HJ, Nyflot MJ, Apisarnthanarax S: Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients. EJNMMI Res. 2016 Dec;6(1):57. doi: 10.1186/s13550-016-0212-9. Epub 2016 Jun 27. [Article]
- Zuckerman E, Slobodin G, Sabo E, Yeshurun D, Naschitz JE, Groshar D: Quantitative liver-spleen scan using single photon emission computerized tomography (SPECT) for assessment of hepatic function in cirrhotic patients. J Hepatol. 2003 Sep;39(3):326-32. [Article]
- External Links
- KEGG Drug
- D06048
- PubChem Compound
- 76957057
- PubChem Substance
- 347827842
- 1423270
- ChEMBL
- CHEMBL1201529
- FDA label
- Download (4.69 MB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Diagnostic Eyelid Sebaceous Gland Carcinoma 1 2 Completed Diagnostic Dyspeptic Subjects 1 Not Available Recruiting Diagnostic Hepatocellular Carcinoma / Intrahepatic Cholangiocarcinoma / Stage IV Liver Cancer / Stage IVA Liver Cancer / Stage IVB Liver Cancer / Vascular Thrombosis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Kit Intravenous; Oral; Subcutaneous 18.1 mg/10mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.608 mg/mL ALOGPS logP 0.82 ALOGPS logP 4.76 Chemaxon logS -2.6 ALOGPS Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 46.05 m3·mol-1 Chemaxon Polarizability 20.4 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at November 30, 2015 19:10 / Updated at October 09, 2021 02:48